乳腺癌中的ADAM和ADAMTS蛋白酶:分子机制和治疗影响
Chanchal Badhai1, Manju Rawat Singh1, Shradha Devi Dwivedi1
1University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India.
Clinical breast cancer
|January 9, 2026
概括
分解蛋白和金属蛋白酶 (ADAMs和ADAMTSs) 是乳腺癌中的关键蛋白酶,驱动或抑制瘤生长. 准这些蛋白酶为改善患者治疗结果提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 乳腺癌是全球癌症死亡的主要原因,发病率不断增加.
- 分解蛋白和金属蛋白酶 (ADAMs) 和具有血栓蛋白动机的ADAMs (ADAMTSs) 是参与癌症进展的蛋白酶家族.
- 这些蛋白酶调节关键的瘤信号通路,包括EGFR,PI3K/AKT/mTOR,TNF-α,Notch和JAK-STAT.
研究的目的:
- 审查最近在乳腺癌中ADAMs和ADAMTSs的作用方面的进展.
- 要突出它们在促进或抑制瘤发生的双重功能.
- 探索针对这些蛋白酶的治疗策略,用于精确瘤学.
主要方法:
- 文献综述综合了乳腺癌中ADAMs和ADAMTSs的当前研究.
- 对它们参与瘤信号传递和瘤进展/抑制的分析.
- 评估治疗方式,包括小分子抑制剂,RNA干扰和纳米载体药物输送.
主要成果:
- ADAM10和ADAM17促进特定乳腺癌亚型 (HER2阳性,三阴性) 的侵袭和转移,作为生物标志物和治疗点.
- 某些ADAMTS成员表现出瘤抑制功能,抑制血管生成和细胞外矩阵重塑.
- 像iRhom蛋白质这样的调控辅因子增加了蛋白质溶解网络的复杂性.
结论:
- 在乳腺癌治疗中,ADAM/ADAMTS蛋白酶是有前途的可用药物标.
- 有针对性的干预措施,包括小分子抑制剂和RNA干扰,显示出改善临床结果的潜力.
- 表观遗传调节,翻译后修改和先进诊断进一步强调了它们在精确瘤学中的价值.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...